ERBB2 and non-small cell lung carcinoma: Two phase II trials of afatinib in NSCLC patients with HER2 mutations were performed in post-progression patients; these trials revealed modest clinical benefits, i.e., ORR of 0%–7.7%, DCR of 53.9%–61.1%, median PFS of 2.8–4.0 months and median OS of 10–14 months.